Empagliflozin: a new era in the treatment of diabetes mellitus type 2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of a targe study EMPA-REG OUTCOME dedicated to the assessment of the possible increase in patient survival by reducing the total and cardiovascular mortality against the background of use of empagliflozin. It is concluded that empagliflozin represents a fundamentally new class of drugs with innovative mechanism of action not related to the insulin effects or insulin secretion. Obviously, clear evidence of pronounced protective effects on kidneys and cardiovascular system, and the ability to reduce total and cardiovascular mortality after 3 months of therapy allow empagliflozin to occupy a special place in the algorithms for the management of patients with type 2 diabetes mellitus.

Full Text

Restricted Access

About the authors

Tatiana Yulievna Demidova

Russian Medical Academy of Postgraduate Education

Email: t.y.demidova@gmail.com
MD, professor, professor of the Department of endocrinology

Vladimir Vladimirovich Salukhov

S.M. Kirov Military Medical Academy

Email: vlasaluk@yandex.ru
MD, Head of the 1st Department of therapy for postgraduate education

References

  1. International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels, Belgium: International Diabetes Federation, 2014.
  2. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E. EMPA-REG OUTCOME Investigators (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:2117-28.
  3. DeFronzo R.A., Davidson J.A., Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012;14(1):5-14.
  4. Abdul-Ghani M.A., Norton L., Defronzo R.A. Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes. Endocr. Rev. 2011;32:515-31.
  5. Merovci A., Solis-Herrera C., Daniele G., Eldor R., Fiorentino T.V., Tripathy D., Xiong J., Perez Z., Norton L., Abdul-Ghani M.A., DeFronzo R.A. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 2014;124:509-14.
  6. Ferrannini E., Muscelli E., Frascerra S., Baldi S., Mari A., Heise T., Broedl U.C., Woerle H.J. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 2014;124:499-508.
  7. Neel J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am. J. Hum. Genet. 1962;14:353-62.
  8. Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.M., Sugg J., Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 2012;97:1020-31.
  9. Lambers Heerspink H.J., de Zeeuw D., Wie L., Leslie B., List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013;1 5:853-62.
  10. Kimura G., Brenner B.M. The renal basis for salt sensitivity in hypertension. In: Laragh J.H., Brenner B.M., editors. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1995. P. 1569-88.
  11. McFarlane S.I., Sowers J.M. Treatment of diabetes and hypertension. In: Izzo Jr J.L., Black H.R., editors. Hypertension primer. 3rd ed. Dallas: The Council on High Blood Pressure Research. American Heart Association; 2003. P. 488-91.
  12. Suzuki M., Kimura Y., Tsushima M., Harano Y. Association of insulin resistance with salt sensitivity and nocturnal fall of blood pressure. Hypertension. 2000;35:864-8.
  13. Kimura G., Uzu T., Nakamura S., Inenaga T., Fujii T. High sodium sensitivity and glomerular hypertension / hyperfiltration in primary aldosteronism. J. Hypertens. 1996;14:1463-8.
  14. Fukuda M., Kimura G. Pathophysiology of antihypertensive therapy with diuretics. Hypertens. Res. 2006;29:645-53.
  15. Lambers Heerspink H.J., de Zeeuw D., Wie L., Leslie B., List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013;1 5:853-62.
  16. Sha S., Polidori D., Heise T., Natarajan J., Farrell K., Wang S.S., Sica D., Rothenberg P., Plum-Mörschel L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2014;16:1087-95.
  17. Lovshin J.A., Gilbert R.E. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr. Hypertens. Rep. 2015;17:551.
  18. Uzu T., Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1999;100:1635-8.
  19. Uzu T., Ishikawa K., Fujii T., Nakamura S., Inenaga T., Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1997;96:1859-62.
  20. Kimura G. Kidney and circadian blood pressure rhythm. Hypertension. 2008;51:827-8.
  21. Kimura G., Dohi Y., Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens. Res. 2010;33:51 5-20.
  22. Baker W.L., Smyth L.R., Riche D.M., Bourret E.M., Chamberlin K.W., White W.B. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J. Am. Soc. Hypertens. 2014;8:262-75.
  23. Oliva R.V., Bakris G.L. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 2014;8:330-9.
  24. Weber M.A., Mansfield T.A., Cain V.A., Iqbal N., Parikh S., Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebocontrolled, phase 3 study. Lancet Diabetes Endocrinol 2016;4:211-20.
  25. Oliva R.V., Bakris G.L. Blood pressure effects of sodium- glucose co-transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 2014;8:330-9.
  26. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 2015;66:255-70.
  27. Quamme G.A. Renal magnesium handling: new insights in understanding old problems. Kidney Int. 1997;52:1 180-95.
  28. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):S14-80.
  29. Marre M., Puig J.G., Kokot F., Fernandez M., Jermendy G., Opie L., Moyseev V., Scheen A., lonescu-Tirgoviste C., Saldanha M.H., Halabe A., Williams B., Mion Junior D., Ruiz M., Hermansen K., Tuomilehto J., Finizola B., Gallois Y., Amouyel P., Ollivier J.P., Asmar R. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004;22:1613-22.
  30. Bakris G.L., Toto R.D, McCullough P.A., Rocha R., Purkayastha D., Davis P. Effects of different ACE inhibitor combinations on albumi.nuria: results of the GUARD study. Kidney Int. 2008;73:1303-9.
  31. Baker W.L., Smyth L.R., Riche D.M., Bourret E.M., Chamberlin K.W., White W.B. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J. Am. Soc. Hypertens. 2014;8:262-75.
  32. Lovshin J.A., Gilbert R.E. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr. Hypertens. Rep. 2015;17:551.
  33. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., Norgiolini S., Bracco C., Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-9.
  34. Cherney D.Z., Perkins B.A., Soleymanlou N., Maione M., Lai V., Lee A., Fagan N.M., Woerle H.J., Johansen O.E., Broedl U.C., von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587-97.
  35. Abdul-Ghani M.A., Norton L., DeFronzo R.A. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am. J. Physiol. Renal. Physiol. 2015;309:F889-900

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies